cCAM Biotherapeutics, a company developing drugs to treat cancer, has closed on an undisclosed amount of Series A financing. The round was led by Arkin Holdings and included participation from OrbiMed’s Israel Partners, Pontifax and F.Hoffmann La Roche, the company said.  cCAM Biotherapeutics is based in Israel.

PRESS RELEASE

cCAM Biotherapeutics, a biopharmaceutical company focused on the discovery and development of novel immunomodulatory drugs for cancer, announced today the completion of its Series A financing . The round was led by Arkin Holdings and included participation from OrbiMed’s Israel Partners, Pontifax and F.Hoffmann La Roche. ROG.VX.

cCAM Biotherapeutics is a pre-clinical stage company developing immunotherapies for cancer. cCAM’s lead agent, CM-10,  is an immunomodulatory humanized monoclonal antibody that harnesses the patient’s immune system to attack tumors. CM-10 targets CEACAM1, a receptor newly characterized as an immune checkpoint used by cancer cells to suppress the immune system. Upon binding to CEACAM1, CM-10 leads to a cancer specific immune response.

“We are very pleased to expand our circle of industry-leading investors,” said Dr. Tehila Ben Moshe, cCAM Bio’s CEO. “With our series A complete, we are in a position to advance our lead antibody through a proof of concept study in humans.”